Noxopharm (ASX:NOX) Presentation, FNN Investor Event, February 2019, Sydney

Company Presentations

Noxopharm Limited (ASX:NOX) CEO and Chief Medical Officer, Dr Greg van Wyk presents on the company's clinical trials for late stage prostate cancer, key outcomes and timelines at FNN's Investor Event.

Key points:

  • An Australian drug development company with a focus on Oncology
  • Aims to significantly change the management of cancer
  • A diverse, highly skilled, broadly experienced team
  • Veyonda® is an innovative formulation of anti-cancer agent, idronoxil
  • Aims to make a broad range of cancers more sensitive to radiotherapy and chemotherapy
  • Two prostate cancer trials ongoing
  • Aims to include a share of the 2026 projected ~ US$14B annual prostate cancer market

For more watch CEO and Chief Medical Officer Dr Greg van Wyk present.